We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to ...

Johnson & Johnson (NYSE:JNJ – Get Free Report) was the target of some unusual options trading on Thursday. Stock traders purchased 58,414 call options on the stock. This is an increase of ...

Sanctuary Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.4% during the fourth quarter, ...

It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have added about 8.9% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 consecutive years, making it a Dividend King. Between Johnson & Johnson's strong ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

If you want upside with a smoother ride than an individual stock, consider the High-Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception. Johnson & Johnson ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However ...